
Justin M Watts

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/12127445/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Ivosidenib induces deep durable remissions in patients with newly diagnosed IDH1-mutant acute myeloid leukemia. Blood, 2020, 135, 463-471.	1.4	266
2	Advances in Acute Myeloid Leukemia: Recently Approved Therapies and Drugs in Development. Cancers, 2020, 12, 3225.	3.7	52
3	KB004, a first in class monoclonal antibody targeting the receptor tyrosine kinase EphA3, in patients with advanced hematologic malignancies: Results from a phase 1 study. Leukemia Research, 2016, 50, 123-131.	0.8	50
4	Oncogenic TRK fusions are amenable to inhibition in hematologic malignancies. Journal of Clinical Investigation, 2018, 128, 3819-3825.	8.2	45
5	Ex-vivo sensitivity profiling to guide clinical decision making in acute myeloid leukemia: A pilot study. Leukemia Research, 2018, 64, 34-41.	0.8	41
6	Clinical Responsiveness to All-trans Retinoic Acid Is Potentiated by LSD1 Inhibition and Associated with a Quiescent Transcriptome in Myeloid Malignancies. Clinical Cancer Research, 2021, 27, 1893-1903.	7.0	23
7	Olutasidenib (FT-2102), an IDH1m Inhibitor As a Single Agent or in Combination with Azacitidine, Induces Deep Clinical Responses with Mutation Clearance in Patients with Acute Myeloid Leukemia Treated in a Phase 1 Dose Escalation and Expansion Study. Blood, 2019, 134, 231-231.	1.4	23
8	Telomere length and associations with somatic mutations and clinical outcomes in acute myeloid leukemia. Leukemia Research, 2016, 49, 62-65.	0.8	17
9	Acute myeloid leukemia presenting with panhypopituitarism or diabetes insipidus: a case series with molecular genetic analysis and review of the literature. Leukemia and Lymphoma, 2014, 55, 2125-2129.	1.3	15
10	Melanoma and nonâ€melanoma skin cancers in hairy cell leukaemia: a Surveillance, Epidemiology and End Results population analysis and the 30â€year experience at Memorial Sloan Kettering Cancer Center. British Journal of Haematology, 2015, 171, 84-90.	2.5	14
11	Younger adults with acute myeloid leukemia in remission for ≥3 years have a high likelihood of cure: The ECOG experience in over 1200 patients. Leukemia Research, 2014, 38, 901-906.	0.8	10
12	A Case of AML Characterized by a Novel t(4;15)(q31;q22) Translocation That Confers a Growth-Stimulatory Response to Retinoid-Based Therapy. International Journal of Molecular Sciences, 2017, 18, 1492.	4.1	10
13	Alisertib (MLN8237), an Oral Selective Inhibitor of Aurora Kinase a, Has Clinical Activity and Restores GATA1 Expression in Patients with Myelofibrosis. Blood, 2018, 132, 688-688.	1.4	8
14	Telomere Length Is Associated with Specific Mutations and Mutation Classes in Patients with Acute Myeloid Leukemia. Blood, 2014, 124, 2280-2280.	1.4	8
15	Clinical Utility of Morphological Evaluation of Day 14 Bone Marrow Biopsies in Acute Myeloid Leukemia Patients Undergoing Standard Induction Chemotherapy: Time to Change Practice?. Blood, 2014, 124, 1004-1004.	1.4	4
16	Early Detection of Myelodysplastic Syndromes: Maximizing the Utility of Automated Hematology. Blood, 2016, 128, 5527-5527.	1.4	1
17	Treatment breakthroughs for the management of acute myeloid leukemia. International Journal of Hematologic Oncology, 2012, 1, 121-132.	1.6	0
18	Leveraging Hypomethylating Agents for Better MDS Therapy. Current Hematologic Malignancy Reports, 2018, 13, 507-515.	2.3	0

JUSTIN M WATTS

#	Article	IF	CITATIONS
19	Increased Incidence Of Melanoma and Non-Melanoma Skin Cancers In Patients With Hairy Cell Leukemia: A Single Institution Experience With 267 Patients From Memorial Sloan-Kettering Cancer Center. Blood, 2013, 122, 5274-5274.	1.4	0
20	Sodium Salicylate Has a Priming Effect When Combined with Azacitidine in Pre-Clinical Models of AML. Blood, 2014, 124, 2300-2300.	1.4	0
21	Characterization of Ntrk fusions and Therapeutic Response to Ntrk Inhibition in Hematologic Malignancies. Blood, 2017, 130, 794-794.	1.4	0